3 Dividend-Paying Pharmaceutical Stocks To Buy This Summer

Analysts expect PFE’s EPS and revenue to increase 43.1% and 63%, respectively, year-over-year to $1.03 and $19.77 billion for the quarter ending September 30, 2021. It surpassed consensus EPS estimates in three of the trailing four quarters.

Last month, Myovant Sciences Ltd. (MYOV) and PFE announced that the U.S. FDA had approved MYFEMBREE, the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. This is expected to boost the company’s revenues. The stock has gained 15.8% over the past three months to close yesterday’s trading session at $38.79.

PFE’s bright prospects are also apparent in its POWR Ratings. The stock has an overall A rating, which equates to Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

It has a B grade for Value, Quality, Stability, and Growth. Click here to see the additional POWR ratings for PFE (Momentum and Sentiment). PFE is ranked #5 of 230 stocks in the Medical-Pharmaceuticals industry.

AbbVie Inc. (ABBV)

Research-based biopharmaceutical company ABBV develops and sells pharmaceutical products worldwide. Its products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology.

ABBV’s dividend pay-outs have grown at an 18.1% CAGR  over the past five years and 19.1% over the past three years. While its four-year average dividend yield is 4.4%, its current dividend translates to a 4.67% yield. It paid a $1.30 quarterly dividend on May 14, 2021.

The company’s revenue increased 50.9% year-over-year to $13.01 billion for the first quarter, ended March 31, 2021. ABBV’s net income was $3.55 billion, which represents an 18% year-over-year increase. Its adjusted EPS came in at $2.95, up 21.9% from the same period last year.

ABBV’s EPS is expected to increase 31.6% year-over-year to $3.08 for the current quarter, ending June 30, 2021. It surpassed the Street’s EPS estimates in each of the trailing four quarters. Analysts expect its revenue to increase 34.9% year-over-year to $13.60 billion in the current quarter.

View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.